News

IDL Biotech licenses its manual ELISA tumor marker product line to Beckman Coulter Diagnostics

Jan 8, 2021

IDL Biotech wants to focus on rapid diagnostic tests and automated assays of its tumor markers. By licensing the platform ELISA to Beckman Coulter, we can focus our resources on streamlining and developing the other platforms,” said Gunnar Wahlberg, CEO of IDL Biotech.

IDL Biotech announced it has signed an agreement with Beckman Coulter for licensing IDL’s entire range of manual ELISA tumor markers. The licensing agreement provides Beckman Coulter with global sales rights and enables IDL to sell material for production and to receive royalties. The agreement has been formally countersigned by Immunotech, a Beckman Coulter subsidiary.

The tumor markers included in the ELISA platform are TPS®, TPAcyk™, MonoTotal® and UBC®.

Read the full press release here (Swedish)

IDL Diagnostics and concile at WHX Labs Dubai

Feb 20, 2026 | ,

Last week, IDL Diagnostics participated as an exhibitor at WHX Labs Dubai together with concile as part of the recently announced joint venture. The main focus is on delivering multiple biomarkers across different POC reader configurations and supporting infection,...

read more

Meet us at WHX Labs Dubai 10-13 February

Feb 2, 2026 | ,

We will be co-exhibiting together with our partner concile at Booth SA.A55. Come by our booth and learn more about our products and how quantitative point-of-care testing can be used to provide accurate and rapid results.

read more